Market capitalization | $638.25m |
Enterprise Value | $210.52m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 842.08 |
P/S ratio (TTM) P/S ratio | 2,553.00 |
P/B ratio (TTM) P/B ratio | 1.46 |
Revenue growth (TTM) Revenue growth | -97.46% |
Revenue (TTM) Revenue | $250.00k |
As a Free StocksGuide user, you can view scores for all 6,945 stocks worldwide.
13 Analysts have issued a Pliant Therapeutics Inc forecast:
13 Analysts have issued a Pliant Therapeutics Inc forecast:
Dec '23 | |
Current assets | 506 506 |
Fixed assets | 6.65 6.65 |
Total Assets | 512 512 |
Dec '23 | |
Equity | 474 474 |
Debt capital | 39 39 |
Total Capital | 512 512 |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrotic in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which has completed Phase Ia single ascending dose/ multiple ascending dose trails and Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also develops PLN-1474, small-molecule selective inhibitor of avß1, which is Phase 1 clinical trials for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. Pliant Therapeutics, Inc. was founded in 2015 and is based in South San Francisco, California.
Head office | United States |
CEO | Bernard Coulie |
Employees | 158 |
Founded | 2015 |
Website | www.pliantrx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.